Radiopharm Strengthens Ties with Lantheus Through $5 Million Investment

Radiopharm Theranostics Limited ( (AU:RAD) ) has issued an update.

Radiopharm Theranostics Limited announced a private placement of ordinary shares to Lantheus Holdings Inc., raising US$5 million. This investment increases Lantheus’s stake in Radiopharm to 12.16%, making it the largest shareholder. The funds will support the development of Radiopharm’s clinical pipeline, enhancing its position in the radiopharmaceutical industry. The placement was made at a 150% premium to the last traded price, signifying strong investor confidence. This development is expected to strengthen the collaboration between Radiopharm and Lantheus, potentially improving patient outcomes through advanced radiopharmaceutical solutions.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company that focuses on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company, listed on the ASX since November 2021, has a deep pipeline of differentiated molecules, including peptides, small molecules, and monoclonal antibodies, in pre-clinical and clinical development stages targeting various solid tumor cancers.

YTD Price Performance: 20.0%

Average Trading Volume: 7,572,663

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$52.82M

For an in-depth examination of RAD stock, go to TipRanks’ Stock Analysis page.